(VIANEWS) - Digital Turbine (APPS), Rent-A-Center (RCII), Antares Pharma (ATRS) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Digital Turbine (APPS)
248.7% sales growth and 18.14% return on equity
Digital Turbine, Inc., through its subsidiaries, provides media and mobile communication products and solutions for mobile operators, application advertisers, publishers, device original equipment manufacturers (OEMs), and other third parties.
Digital Turbine's sales growth this year is expected to be 284% and 32.6% for next year.
Year-on-year quarterly revenue growth grew by 337.6%, now sitting on 706.49M for the twelve trailing months.
Volume
Today's last reported volume for Digital Turbine is 3378020 which is 16.54% below its average volume of 4047830.
Digital Turbine's sales growth is a negative 0% for the present quarter and 248.7% for the next. The company's growth estimates for the current quarter and the next is 104.8% and 60%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.14%.
Volatility
Digital Turbine's last day, last week, and last month's current volatility was 3.45%, 7.00%, and 3.34%, respectively.
Digital Turbine's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.92% (day), 7.93% (last week), and 5.39% (last month), respectively.
Digital Turbine's Stock Yearly Top and Bottom Value
Digital Turbine's stock is valued at $70.53 at 10:22 EST, way below its 52-week high of $102.56 and way higher than its 52-week low of $32.74.
Digital Turbine's Moving Average
Digital Turbine's worth is way under its 50-day moving average of $78.55 and higher than its 200-day moving average of $68.02.2. Rent-A-Center (RCII)
70% sales growth and 25.98% return on equity
Rent-A-Center, Inc., together with its subsidiaries, leases household durable goods to customers on a lease-to-own basis.
Rent-A-Center's sales growth this year is anticipated to be 64.5% and 13.8% for next year.
Year-on-year quarterly revenue growth grew by 65.9%, now sitting on 4.13B for the twelve trailing months.
Volume
Today's last reported volume for Rent-A-Center is 1983060 which is 243.83% above its average volume of 576749.
Rent-A-Center's sales growth for the next quarter is 70%. The company's growth estimates for the present quarter and the next is 44.2% and 75.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 25.98%.
Volatility
Rent-A-Center's last day, last week, and last month's current volatility was 3.80%, 7.11%, and 3.39%, respectively.
Rent-A-Center's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 9.80% (day), 7.91% (last week), and 4.44% (last month), respectively.
Rent-A-Center's Stock Yearly Top and Bottom Value
Rent-A-Center's stock is valued at $43.46 at 10:22 EST, way under its 52-week high of $67.76 and way above its 52-week low of $29.95.
Rent-A-Center's Moving Average
Rent-A-Center's worth is way under its 50-day moving average of $55.65 and way below its 200-day moving average of $57.70.3. Antares Pharma (ATRS)
17.2% sales growth and 68.23% return on equity
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas.
Antares Pharma's sales growth this year is anticipated to be 25.7% and 24.1% for next year.
Year-on-year quarterly revenue growth grew by 38.9%, now sitting on 171.2M for the twelve trailing months.
Volume
Today's last reported volume for Antares Pharma is 122908 which is 79.61% below its average volume of 603072.
Antares Pharma's sales growth for the next quarter is 17.2%. The company's growth estimates for the current quarter and the next is a negative 0% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 68.23%.
Volatility
Antares Pharma's last day, last week, and last month's current volatility was 7.10%, 4.38%, and 2.43%, respectively.
Antares Pharma's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 8.89% (day), 5.78% (last week), and 3.69% (last month), respectively.
Antares Pharma's Stock Yearly Top and Bottom Value
Antares Pharma's stock is valued at $3.76 at 10:22 EST, way under its 52-week high of $5.07 and way higher than its 52-week low of $2.79.
Antares Pharma's Moving Average
Antares Pharma's value is above its 50-day moving average of $3.62 and under its 200-day moving average of $3.97.4. Primerica (PRI)
16.4% sales growth and 22.91% return on equity
Primerica, Inc., together with its subsidiaries, provides financial products to middle income households in the United States and Canada.
Primerica's sales growth this year is expected to be 21.6% and 4% for next year.
Year-on-year quarterly revenue growth grew by 18.9%, now sitting on 2.63B for the twelve trailing months.
Volume
Today's last reported volume for Primerica is 196689 which is 88.09% above its average volume of 104568.
Primerica's sales growth for the next quarter is 16.4%. The company's growth estimates for the current quarter and the next is 7.2% and 31%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 22.91%.
Volatility
Primerica's last day, last week, and last month's current volatility was 7.62%, 2.74%, and 1.50%, respectively.
Primerica's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 7.89% (day), 3.42% (last week), and 2.18% (last month), respectively.
Primerica's Stock Yearly Top and Bottom Value
Primerica's stock is valued at $162.77 at 10:22 EST, under its 52-week high of $179.51 and way higher than its 52-week low of $121.38.
Primerica's Moving Average
Primerica's worth is higher than its 50-day moving average of $162.70 and higher than its 200-day moving average of $155.50.5. United Rentals (URI)
15.5% sales growth and 22.24% return on equity
United Rentals, Inc., through its subsidiaries, operates as an equipment rental company.
United Rentals's sales growth this year is anticipated to be 11.7% and 7.3% for next year.
Year-on-year quarterly revenue growth grew by 17.9%, now sitting on 8.81B for the twelve trailing months.
Volume
Today's last reported volume for United Rentals is 342521 which is 40.88% below its average volume of 579424.
United Rentals's sales growth for the next quarter is 15.5%. The company's growth estimates for the current quarter and the next is 26.3% and 30%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 22.24%.
Volatility
United Rentals's last day, last week, and last month's current volatility was 0.21%, 1.01%, and 1.54%, respectively.
United Rentals's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 5.73% (day), 2.90% (last week), and 2.89% (last month), respectively.
United Rentals's Stock Yearly Top and Bottom Value
United Rentals's stock is valued at $391.50 at 10:22 EST, under its 52-week high of $414.99 and way higher than its 52-week low of $198.74.
United Rentals's Moving Average
United Rentals's value is higher than its 50-day moving average of $359.16 and way above its 200-day moving average of $336.31.6. United Therapeutics Corporation (UTHR)
10.5% sales growth and 13.99% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
United Therapeutics Corporation's sales growth this year is expected to be 12.9% and 10.3% for next year.
Year-on-year quarterly revenue growth grew by 23.3%, now sitting on 1.59B for the twelve trailing months.
Volume
Today's last reported volume for United Therapeutics Corporation is 407320 which is 7.96% above its average volume of 377281.
United Therapeutics Corporation's sales growth for the next quarter is 10.5%. The company's growth estimates for the current quarter and the next is a negative 7.3% and 63.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.99%.
Volatility
United Therapeutics Corporation's last day, last week, and last month's current volatility was 0.43%, 1.88%, and 1.40%, respectively.
United Therapeutics Corporation's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.10% (day), 4.02% (last week), and 2.85% (last month), respectively.
United Therapeutics Corporation's Stock Yearly Top and Bottom Value
United Therapeutics Corporation's stock is valued at $202.30 at 10:22 EST, below its 52-week high of $216.90 and way higher than its 52-week low of $129.43.